You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Current Advances in Osteosarcoma edited by Dr. Eugenie S. Kleinerman summarizes molecular and genetic characteristics, new therapeutic ideas, and biological characteristics that have been uncovered in the past 10 years. Osteosarcoma is an aggressive malignant neoplasm and it is also the most common histological form of bone cancer. It accounts for approximately 56% of new bone tumors, making it the most primary malignant bone tumor in children and adolescents. The lungs are the most common site of metastases and once osteosarcoma spreads to the lungs, it is very difficult to treat. To improve the outcome of this disease, the biology of osteosarcoma needs to be better understood. There are numerous investigators around the world who have made seminal discoveries about the important molecular pathways and genetic alterations that contribute to the development and metastases of osteosarcoma. Other investigators have proposed novel therapeutic strategies including some based on the molecular and genetic phenotype of the disease. Current Advances in Osteosarcoma summarizes all of these new discoveries in one singular text, which will help move the field forward.
This thoroughly revised second edition is an up-to-date overview of the new advances in the knowledge of the basic science in sarcoma and osteosarcoma. It features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, this essential volume also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focuse...
This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigene...
Each issue lists papers published during the preceding year.
Novel Approaches to Cancer Chemotherapy compiles theories in tumor biology, emphasizing their potential use in developing therapeutic approaches to cancer therapy. This book emphasizes the unique property of a cancer cell and describes in detail how a novel therapeutic approach can be developed. This compilation consists of 11 chapters. Chapters 1, 2, 5, 6, and 7 deal with emerging areas of cancer therapy, such as the use of interferon, monoclonal antibodies, liposomes, lymphokines, and immunomodulators. The rest of the chapters cover some of the biochemical and enzyme targets in cancer cells, such as polyamines, prostaglandin, thromboxane, leukotrienes, 5a-reductase, aromatase, cell membrane glycoproteins, and sodium flux. The developments in relation to cancer therapy are mentioned in chapters dealing with biochemical approaches. This book is valuable to biologists, biochemists, immunologists, and molecular biologists intending to exploit the unique properties of cancer cells.
Pediatric and Adolescent Osteosarcoma provides a historical review of the nature of osteosarcoma and the conflict that accompanied the introduction of adjuvant therapy for osteosarcoma culminating in accepted and prevailing methods of current therapy. It outlines concepts in Epidemiology and Etiology, and provides chapters on pathology and radiologic characteristics of osteosarcoma, surgical therapy tailored specifically for treatment of primary tumors in pediatric/adolescent age group, treatment of pulmonary and extra pulmonary metastases and complications, as well as the role of radiation therapy. The volume concludes with a review of differences and similarities in the management of osteo...
Childhood cancer was almost always fatal before 1970. Today, 80% of ch- dren diagnosed with cancer will survive at least 5 years; 70% will be cured. However, cancer continues to be the leading cause of nonaccident-related deaths in children. More children die each year from cancer than from c- tic ?brosis, diabetes, asthma, AIDS, and congenital abnormalities combined. Nine children die from cancer every school day. Despite the fact that pediatric cancers account for only a small p- centage of the total cancer burden, more effective therapies are needed to improve mortality rates in children. Therefore, our research priority must be the development of new agents and new therapies for childhoo...
The Methods in Molecular Medicine series is intended as a resource for both novice and experienced investigators attempting to diversify their tech- logical base in research. Lung Cancer: Volume 1: Molecular Pathology Me- ods and Reviews presents an overview of the current status of assays employed to detect and characterize the multitude of pathologies that contribute to the development of this deadly disease. As with all volumes in the Methods in Molecular Medicine series, the reader should find that each methods-based chapter provides clear instructions for the performance of various protocols, supplemented by additional technical notes that provide valuable insight. These notes are desig...